Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y2Z4
UPID:
SYYM_HUMAN
Alternative names:
Tyrosyl-tRNA synthetase
Alternative UPACC:
Q9Y2Z4; D3DUW8; Q9H817
Background:
Tyrosine--tRNA ligase, mitochondrial, also known as Tyrosyl-tRNA synthetase, plays a crucial role in protein synthesis. It catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction, involving the activation of tyrosine by ATP to form Tyr-AMP and its subsequent transfer to the acceptor end of tRNA(Tyr).
Therapeutic significance:
The protein is implicated in Myopathy with lactic acidosis and sideroblastic anemia 2, a rare disorder affecting skeletal muscle and bone marrow. This association highlights its potential as a target for therapeutic intervention in mitochondrial diseases.